Thrombotic Thrombocytopenic Purpura Associated with von Willebrand Factor-Cleaving Protease (ADAMTS13) Deficiency in Children

ABSTRACT

The physiopathology of thrombotic thrombocytopenic purpura (TTP) has been clarified since 1998, when it was shown that TTP in adults was most often associated with an acquired deficiency of von Willebrand factor-cleaving protease (ADAMTS13) due to autoantibodies, whereas TTP in children was most often associated with a hereditary autosomal recessive severe deficiency of ADAMTS13. The hereditary form of TPP (Upshaw-Schulman syndrome) is a very rare but life-threatening disease if adequate treatment (plasma therapy) is not administered. First manifestations occur before age 10 in two thirds of cases and as soon as birth in most cases. The subsequent course is characterized by recurrent hemolytic and thrombocytopenic crises, with intervals between relapses from every 3 to 4 weeks in two thirds of cases to several months or years in one third of cases. TTP crises are associated with cerebral vascular accidents in at least 30% of patients, with a risk of neurologic sequelae in approximately 20% of patients. Renal involvement includes frequent acute renal failure due to hemoglobinuria and/or thrombotic microangiopathy during hemolytic crisis and progressive renal deterioration in approximately 50% of cases, leading to chronic or end-stage renal failure in approximately 20% of patients. The clinical phenotype may vary from the typical congenital recurrent TTP. Some mild forms are limited to a fluctuating thrombocytopenia and may be misdiagnosed as idiopathic thrombocytopenic purpura. Phenotypic variability may be observed within a single family, which suggests a role of modifier genes. Fresh frozen plasma (FFP) replaces active ADAMTS13. Ten milliliters per kilogram FFP every 2 to 4 weeks suffices to maintain remission. FFP infusions are best used preventively, given that rescue infusions may not prevent central nervous system and renal involvement. It is hoped that plasmatic or recombinant purified ADAMTS13 will be available in the years to come.

Thrombotic thrombocytopenic purpura - hemolytic uremic syndrome - thrombotic microangiopathy - ADAMTS13 - fresh frozen plasma

REFERENCES

• 1 Sadler J E, Moake J L, Miyata T, George J N. Recent advances in thrombotic thrombocytopenic purpura.  Hematology (Am Soc Hematol Educ Program). 2004;  1 407-423
• 2 Dacie J V, Mollison P L, Richardson N, Selwyn J G, Shapiro L. Atypical congenital haemolytic anaemia.  Q J Med. 1953;  22 79-98
• 3 Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis I A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency.  Blood. 1960;  16 943-957
• 4 Monnens L A, Retera R J. Thrombotic thrombocytopenic purpura in a neonatal infant.  J Pediatr. 1967;  71 118-123
• 5 Wallace D C, Lovric A, Clubb J S, Carseldine D B. Thrombotic thrombocytopenic purpura in four siblings.  Am J Med. 1975;  58 724-734
• 6 Upshaw Jr J D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thromcytopenia.  N Engl J Med. 1978;  298 1350-1352
• 7 Rennard S, Abe S. Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome).  N Engl J Med. 1979;  300 368 (Lett)
• 8 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 9 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura with special reference to factor VIII related antigen.  Thromb Res. 1985;  38 469-479
• 10 Chintagumpala M M, Hurwitz R L, Moake J L, Mahoney D H, Steuber C P. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission.  J Pediatr. 1992;  120 49-53
• 11 Azuno Y, Kaku K, Shino K et al.. A congenital variant of thrombotic thrombocytopenic purpura in two siblings.  Intern Med. 1994;  33 752-758
• 12 Karpman D, Holmberg L, Jirgard L, Lethagen S. Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura.  Kidney Int. 1996;  49 190-199
• 13 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87 4223-4234
• 14 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 15 Furlan M, Robles R, Galbusera M et al.. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 16 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87 4235-4244
• 17 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 18 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS 13 gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 19 Studt J D, Kremer Hovinga J A, Alberio L, Bianchi V, von Lämmle B. Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.  Swiss Med Wkly. 2003;  133 325-332
• 20 Tsai H M. Molecular mechanisms in thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 2004;  30 549-557
• 21 Kremer Hovinga J A, Studt J D, Demarmels Biasiutti F et al.. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.  Haematologica. 2004;  89 320-324
• 22 Robson W L, Tsai H M. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy.  Pediatrics. 2002;  109 322-325
• 23 Ashida A, Nakamura H, Yoden A et al.. Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome.  Am J Hematol. 2002;  71 318-322
• 24 Horton T M, Stone J D, Yee D, Dreyer Z, Moake J L, Mahoney D H. Case series of thrombotic thrombocytopenic purpura in children and adolescents.  J Pediatr Hematol Oncol. 2003;  25 336-339
• 25 Schneppenheim R, Budde U, Hassenpflug W, Obser T. Severe ADAMTS-13 deficiency in childhood.  Semin Hematol. 2004;  41 83-89
• 26 Ahmad A, Aggarwal A, Sharma D et al.. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).  Am J Hematol. 2004;  77 171-176
• 27 Galbusera M, Bresin E, Noris M et al.. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.  Blood. 2005;  106 925-928
• 28 Fakhouri F, Vernant J P, Veyradier A et al.. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS 13 deficient-thrombotic thrombocytopenic purpura: a study of 11 cases.  Blood. 2005;  106 1932-1937
• 29 Moake J L. Thrombotic thrombocytopenic purpura and the haemolytic uremic syndrome.  Arch Pathol Lab Med. 2002;  126 1430-1433
• 30 Amoura Z, Costedoat-Chalumeau N, Veyradier A et al.. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome.  Arthritis Rheum. 2004;  50 3260-3264
• 31 Rieger M, Mannucci P M, Hovinga J A et al.. ADAMTS 13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.  Blood. 2005;  106 1262-1267
• 32 Veyradier A, Obert B, Haddad E et al.. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.  J Pediatr. 2003;  142 310-317
• 33 Hunt B J, Lämmle B, Nevard C H, Haycock G B, von Furlan M. Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome.  Thromb Haemost. 2001;  85 975-978
• 34 Tsai H M, Chandler W L, Sarode R et al.. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated haemolytic uremic syndrome.  Pediatr Res. 2001;  49 653-659
• 35 Schneppenheim R, Budde U, Oyen F et al.. Von Willebrand factor cleaving protease and ADAMTS 13 mutations in childhood TTP.  Blood. 2003;  101 1845-1850
• 36 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemeolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.  Best Pract Res Clin Haematol. 2001;  14 437-454
• 37 Haberle J, Kehrel B, Ritter J, Jürgens H, Lämmle B, Furlan M. New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review.  Eur J Pediatr. 1999;  158 883-887
• 38 Allford S L, Harrison P, Lawrie A S, Liesner R, Mackie I J, Machin S J. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura.  Br J Haematol. 2000;  111 1215-1222
• 39 te Loo D M, Levtchenko E, Furlan M, Roosendaal G P, Van Den Heuvel L P. Autosomal recessive inheritance of von Willebrand factor-cleaving protease deficiency.  Pediatr Nephrol. 2000;  14 762-765
• 40 Barbot J, Costa E, Guerra M et al.. Ten years of prophylatic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease.  Br J Haematol. 2001;  113 649-651
• 41 Sasahara Y, Kumaki S, Ohashi Y et al.. Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome.  Int J Hematol. 2001;  74 109-114
• 42 Stark G L, Wallis J P, Allford S L, Hanley J. Chronic relapsing thrombotic thrombocytopenic purpura due to a deficiency of von Willebrand factor-cleaving protease activity.  Br J Haematol. 2002;  117 251-252
• 43 Kentouche K, Budde U, Furlan M, Scharfe V, Schneppenheim R, Zintl F. Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma.  Acta Paediatr. 2002;  91 1056-1059
• 44 Assink K, Schiphorst R, Allford S et al.. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.  Kidney Int. 2003;  63 1995-1999
• 45 Savasan S, Lee S K, Ginsburg D, Tsai H M. ADAMTS 13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.  Blood. 2003;  101 4449-4451
• 46 Studt J D, Hovinga J A, Furlan M, Lämmle B. Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS 13) in congenital thrombotic thrombocytopenic purpura.  Blood. 2003;  102 1148 (Lett)
• 47 Snider C E, Moore J C, Warkentin T E, Finch C N, Hayward C P, Kelton J G. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura.  Am J Hematol. 2004;  77 387-390
• 48 Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B. Two novel ADAMTS 13 gene mutations in thrombotic thrombocytopenic purpura/haemolytic-uremic syndrome (TTP/HUS).  Kidney Int. 2004;  66 955-958
• 49 Matsumoto M, Kokame K, Soejima K et al.. Molecular characterization of ADAMTS 13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.  Blood. 2004;  103 1305-1310
• 50 Schiff D E, Roberts W D, Willert J, Tsai H M. Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS 13 deficiency.  J Pediatr Hematol Oncol. 2004;  26 535-538
• 51 Pimanda J E, Maekawa A, Wind T, Paxton J, Chesterman C N, Hogg P J. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS 13.  Blood. 2004;  103 627-629
• 52 Studt J D, Hovinga J A, Antoine G et al.. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS 13 inhibitor: in vitro inhibition of ADAMTS 13 activity by hemoglobin.  Blood. 2005;  105 542-544
• 53 Deschênes G, Veyradier A, Cloarec S et al.. Plasma therapy in von Willebrand factor protease deficiency.  Pediatr Nephrol. 2002;  17 867-870
• 54 Noris M, Bucchioni S, Galbusera M et al.. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS 13 deficiency and renal involvement.  J Am Soc Nephrol. 2005;  16 1177-1183
• 55 Veyradier A, Lavergne J M, Ribba A S et al.. Ten candidate ADAMTS 13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).  J Thromb Haemost. 2004;  2 424-429
• 56 Kokame K, Matsumoto M, Soejima K et al.. Mutations and common polymorphisms in ADAMTS 13 gene responsible for von Willebrand factor-cleaving protease activity.  Proc Natl Acad Sci USA. 2002;  99 11902-11907
• 57 Bestetti G, Stellari A, Lattuada A et al.. ADAMTS 13 genotype and VWF protease activity in an Italian family.  Thromb Haemost. 2003;  90 955-956
• 58 Antoine G, Zimmerman K, Plaimauer B et al.. ADAMTS 13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS 13.  Br J Haematol. 2003;  120 821-824
• 59 Uchida T, Wada H, Mizutani M et al.. Identification of novel mutations in ADAMTS 13 in an adult patient with congenital thrombotic thrombocytopenic purpura.  Blood. 2004;  104 2081-2083
• 60 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 1999;  81 8-13
• 61 Plaimauer B, Scheiflinger F. Expression and characterization of recombinant human ADAMTS-13.  Semin Hematol. 2004;  41 24-33
• 62 Kinoshita S, Yoshioka A, Park Y D et al.. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.  Int J Hematol. 2001;  74 101-108
• 63 Reiter R A, Knobl P, Varadi K, Turecek P L. Changes in von Willebrand factor-cleaving protease (ADAMTS 13) activity after infusion of desmopressin.  Blood. 2003;  101 946-948
• 64 Mannucci P M, Capoferri C, Canciani M T. Plasma levels of von Willebrand factor regulate ADAMTS 13, its major cleaving-protease.  Br J Haematol. 2004;  126 213-218
• 65 Hara T, Kitano A, Kajiwara T, Kondo T, Sakai K, Hamasaki Y. Factor VIII concentrate-responsive thrombocytopenia, hemolytic anemia, and nephropathy. Evidence that factor VIII: von Willebrand factor is involved in its pathogenesis.  Am J Pediatr Hematol Oncol. 1986;  8 324-328